AbCellera Biologics Inc. Operating Cash Flow
AbCellera Biologics Inc. (ABCL) reported Operating Cash Flow of -$7.60 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Cash Flow › Operating Activities
us-gaap:NetCashProvidedByUsedInOperatingActivities · last filed 2026-08-05
- AbCellera Biologics Inc. net cash provided by (used in) operating activities for the quarter ending 2026-06-30 was $25.92M.
- AbCellera Biologics Inc. net cash provided by (used in) operating activities for the quarter ending 2026-03-31 was -$33.52M.
- AbCellera Biologics Inc. net cash provided by (used in) operating activities for the quarter ending 2025-12-31 was -$34.74M.
- AbCellera Biologics Inc. net cash provided by (used in) operating activities for the quarter ending 2025-09-30 was -$52.59M.
- AbCellera Biologics Inc. net cash provided by (used in) operating activities for fiscal 2025 was -$131.29M.
- AbCellera Biologics Inc. net cash provided by (used in) operating activities for fiscal 2024 was -$108.56M.
- AbCellera Biologics Inc. net cash provided by (used in) operating activities for fiscal 2023 was -$43.88M, a 115.82% decline from fiscal 2022.
- AbCellera Biologics Inc. net cash provided by (used in) operating activities for fiscal 2022 was $277.36M, a 13.40% increase from fiscal 2021.
| Period end | Net Cash Provided by (Used in) Operating Activities 3 month | Net Cash Provided by (Used in) Operating Activities 6 month | Net Cash Provided by (Used in) Operating Activities 9 month | Net Cash Provided by (Used in) Operating Activities 12 month |
|---|---|---|---|---|
| 2026-06-30 | $25.92M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | -$7.60M 10-Q · filed 2026-08-05 | -$42.34M derived: sum of 3 quarters · filed 2026-08-05 | -$94.94M derived: sum of 4 quarters · filed 2026-08-05 |
| 2026-03-31 | -$33.52M 10-Q · filed 2026-05-11 | -$68.27M derived: sum of 2 quarters · filed 2026-05-11 | -$120.86M derived: sum of 3 quarters · filed 2026-05-11 | -$153.26M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-12-31 | -$34.74M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | -$87.34M derived: sum of 2 quarters · filed 2026-02-24 | -$119.74M derived: sum of 3 quarters · filed 2026-08-05 | -$131.29M 10-K · filed 2026-02-24 |
| 2025-09-30 | -$52.59M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | -$85.00M derived: sum of 2 quarters · filed 2026-08-05 | -$96.55M 10-Q · filed 2025-11-06 | -$104.55M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-06-30 | -$32.40M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | -$43.96M 10-Q · filed 2026-08-05 | -$51.96M derived: sum of 3 quarters · filed 2026-08-05 | -$80.84M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-03-31 | -$11.55M 10-Q · filed 2026-05-11 | -$19.55M derived: sum of 2 quarters · filed 2026-05-11 | -$48.44M derived: sum of 3 quarters · filed 2026-05-11 | -$78.40M derived: sum of 4 quarters · filed 2026-05-11 |
| 2024-12-31 | -$8.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | -$36.88M derived: sum of 2 quarters · filed 2026-02-24 | -$66.85M derived: sum of 3 quarters · filed 2026-02-24 | -$108.56M 10-K · filed 2026-02-24 |
| 2024-09-30 | -$28.88M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | -$58.85M derived: sum of 2 quarters · filed 2025-11-06 | -$100.56M 10-Q · filed 2025-11-06 | -$120.17M derived: sum of 4 quarters · filed 2026-02-24 |
| 2024-06-30 | -$29.97M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | -$71.67M 10-Q · filed 2025-08-07 | -$91.28M derived: sum of 3 quarters · filed 2026-02-24 | -$91.39M derived: sum of 4 quarters · filed 2026-02-24 |
| 2024-03-31 | -$41.71M 10-Q · filed 2025-05-08 | -$61.32M derived: sum of 2 quarters · filed 2026-02-24 | -$61.42M derived: sum of 3 quarters · filed 2026-02-24 | -$41.52M derived: sum of 4 quarters · filed 2026-02-24 |
| 2023-12-31 | -$19.61M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | -$19.72M derived: sum of 2 quarters · filed 2026-02-24 | $186.00K derived: sum of 3 quarters · filed 2026-02-24 | -$43.88M 10-K · filed 2026-02-24 |
| 2023-09-30 | -$106.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-04 | $19.80M derived: sum of 2 quarters · filed 2024-11-04 | -$24.27M 10-Q · filed 2024-11-04 | $6.65M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-06-30 | $19.90M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-06 | -$24.16M 10-Q · filed 2024-08-06 | $6.75M derived: sum of 3 quarters · filed 2025-02-27 | -$120.03M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-03-31 | -$44.06M 10-Q · filed 2024-05-07 | -$13.15M derived: sum of 2 quarters · filed 2025-02-27 | -$139.94M derived: sum of 3 quarters · filed 2025-02-27 | $133.08M derived: sum of 4 quarters · filed 2025-02-27 |
| 2022-12-31 | $30.91M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | -$95.87M derived: sum of 2 quarters · filed 2025-02-27 | $177.14M derived: sum of 3 quarters · filed 2025-02-27 | $277.36M 10-K · filed 2025-02-27 |
| 2022-09-30 | -$126.79M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-02 | $146.23M derived: sum of 2 quarters · filed 2023-11-02 | $246.45M 10-Q · filed 2023-11-02 | $229.74M derived: sum of 4 quarters · filed 2024-02-20 |
| 2022-06-30 | $273.01M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-03 | $373.23M 10-Q · filed 2023-08-03 | $356.52M derived: sum of 3 quarters · filed 2024-02-20 | $350.59M derived: sum of 4 quarters · filed 2024-02-20 |
| 2022-03-31 | $100.22M 10-Q · filed 2023-05-04 | $83.51M derived: sum of 2 quarters · filed 2024-02-20 | $77.58M derived: sum of 3 quarters · filed 2024-02-20 | $235.26M derived: sum of 4 quarters · filed 2024-02-20 |
| 2021-12-31 | -$16.71M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-20 | -$22.64M derived: sum of 2 quarters · filed 2024-02-20 | $135.04M derived: sum of 3 quarters · filed 2024-02-20 | $244.58M 10-K · filed 2024-02-20 |
| 2021-09-30 | -$5.93M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-08 | $151.75M derived: sum of 2 quarters · filed 2022-11-08 | $261.30M 10-Q · filed 2022-11-08 | $262.57M derived: sum of 4 quarters · filed 2023-02-21 |
| 2021-06-30 | $157.68M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-09 | $267.23M 10-Q · filed 2022-08-09 | $268.51M derived: sum of 3 quarters · filed 2023-02-21 | $264.70M derived: sum of 4 quarters · filed 2023-02-21 |
| 2021-03-31 | $109.55M 10-Q · filed 2022-05-10 | $110.82M derived: sum of 2 quarters · filed 2023-02-21 | $107.02M derived: sum of 3 quarters · filed 2023-02-21 | $133.00M derived: sum of 4 quarters · filed 2023-02-21 |
| 2020-12-31 | $1.28M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-21 | -$2.52M derived: sum of 2 quarters · filed 2023-02-21 | $23.45M derived: sum of 3 quarters · filed 2023-02-21 | $22.69M 10-K · filed 2023-02-21 |
| 2020-09-30 | -$3.80M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-10 | $22.18M derived: sum of 2 quarters · filed 2021-11-10 | $21.41M 10-Q · filed 2021-11-10 | |
| 2020-06-30 | $25.98M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-13 | $25.21M 10-Q · filed 2021-08-13 | ||
| 2020-03-31 | -$764.00K 10-Q · filed 2021-05-14 | |||
| 2019-12-31 | $2.69M 10-K · filed 2022-02-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ACADIA PHARMACEUTICALS INC (ACAD) | United States | $3.823B | 11.45 |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| Tango Therapeutics, Inc. (TNGX) | United States | $4.154B | -42.53 |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Indivior Pharmaceuticals, Inc. (INDV) | $4.250B | 14.09 | |
| Viking Therapeutics, Inc. (VKTX) | United States | $4.287B | -8.51 |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |
| Enliven Therapeutics, Inc. (ELVN) | United States | $3.307B | -35.07 |
| Arcutis Biotherapeutics, Inc. (ARQT) | United States | $3.303B | 115.47 |